These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36907478)

  • 1. Tripterygium wilfordii protects against an animal model of autoimmune hepatitis.
    Zhang T; Rao Q; Dai M; Wu ZE; Zhao Q; Li F
    J Ethnopharmacol; 2023 Jun; 309():116365. PubMed ID: 36907478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics reveals the role of PPARα in Tripterygium Wilfordii-induced liver injury.
    Dai M; Peng W; Zhang T; Zhao Q; Ma X; Cheng Y; Wang C; Li F
    J Ethnopharmacol; 2022 May; 289():115090. PubMed ID: 35143937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celastrol pretreatment attenuates concanavalin A-induced hepatitis in mice by suppressing interleukin-6/STAT3-interleukin-17 signaling.
    Li D; Chen J; Lin B; Guo Y; Pan J; Yu C; Wan X
    J Gastroenterol Hepatol; 2023 May; 38(5):821-829. PubMed ID: 36967570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii.
    Dai M; Peng W; Lin L; Wu ZE; Zhang T; Zhao Q; Cheng Y; Lin Q; Zhang B; Liu A; Rao Q; Huang J; Zhao J; Gonzalez FJ; Li F
    Phytomedicine; 2023 Dec; 121():155054. PubMed ID: 37738906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FXR activation prevents liver injury induced by
    Peng W; Dai MY; Bao LJ; Zhu WF; Li F
    Xenobiotica; 2021 Jun; 51(6):716-727. PubMed ID: 33704005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celastrol induced the autophagy of spermatogonia cells contributed to tripterygium glycosides-related testicular injury.
    Cui DX; Niu ZC; Tang X; Cai CZ; Xu DQ; Fu RJ; Liu WJ; Wang YW; Tang YP
    Reprod Toxicol; 2024 Jun; 126():108604. PubMed ID: 38703919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celastrol ameliorates acute liver injury through modulation of PPARα.
    Zhao Q; Tang P; Zhang T; Huang JF; Xiao XR; Zhu WF; Gonzalez FJ; Li F
    Biochem Pharmacol; 2020 Aug; 178():114058. PubMed ID: 32470546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celastrol Protects against Cerebral Ischemia/Reperfusion Injury in Mice by Inhibiting Glycolysis through Targeting HIF-1
    Chen M; Liu M; Luo Y; Cao J; Zeng F; Yang L; Yang J; Tao T; Jiang Y
    Oxid Med Cell Longev; 2022; 2022():7420507. PubMed ID: 35035665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatoprotective Role of 4-Octyl Itaconate in Concanavalin A-Induced Autoimmune Hepatitis.
    Yang W; Wang Y; Zhang P; Wang T; Li C; Tong X; Zeng X; Yin Y; Tao K; Li R
    Mediators Inflamm; 2022; 2022():5766434. PubMed ID: 35310452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celastrol functions as an emerging manager of lipid metabolism: Mechanism and therapeutic potential.
    Gu J; Shi YN; Zhu N; Li HF; Zhang CJ; Qin L
    Biomed Pharmacother; 2023 Aug; 164():114981. PubMed ID: 37285754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MVA pathway genes expressions and accumulation of celastrol in Tripterygium wilfordii suspension cells in response to methyl jasmonate treatment.
    Liu YJ; Zhao YJ; Su P; Zhang M; Tong YR; Hu TY; Huang LQ; Gao W
    J Asian Nat Prod Res; 2016 Jul; 18(7):619-28. PubMed ID: 26785825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: Implications for Alzheimer's disease therapy.
    Yang C; Su C; Iyaswamy A; Krishnamoorthi SK; Zhu Z; Yang S; Tong BC; Liu J; Sreenivasmurthy SG; Guan X; Kan Y; Wu AJ; Huang AS; Tan J; Cheung K; Song J; Li M
    Acta Pharm Sin B; 2022 Apr; 12(4):1707-1722. PubMed ID: 35847498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease.
    Zhang W; Wang J; Yang C
    Autophagy; 2022 Jul; 18(7):1740-1742. PubMed ID: 35253615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targets of thunder god vine (Tripterygium wilfordii hook) in rheumatoid arthritis (Review).
    Song X; Zhang Y; Dai E
    Mol Med Rep; 2020 Jun; 21(6):2303-2310. PubMed ID: 32323812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner.
    Lee JY; Lee BH; Kim ND; Lee JY
    J Ethnopharmacol; 2015 Aug; 172():254-60. PubMed ID: 26116162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-responsive gene 1 protects against liver injury caused by concanavalin A via the activation Nrf2/HO-1 pathway and inhibition of ROS activation pathways.
    Yang W; Wang Y; Zhang P; Sun X; Chen X; Yu J; Shi L; Yin Y; Tao K; Li R
    Free Radic Biol Med; 2022 Mar; 182():108-118. PubMed ID: 35231555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Berberine on Concanavalin A-Induced Autoimmune Hepatitis (AIH) in Mice and the Adenosine 5'-Monophosphate (AMP)-Activated Protein Kinase (AMPK) Pathway.
    Wang Y; Zhou L; Li Y; Guo L; Zhou Z; Xie H; Hou Y; Wang B
    Med Sci Monit; 2017 Dec; 23():6150-6161. PubMed ID: 29283990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celastrol, a triterpene extracted from Tripterygium wilfordii Hook F, inhibits platelet activation.
    Hu H; Straub A; Tian Z; Bassler N; Cheng J; Peter K
    J Cardiovasc Pharmacol; 2009 Sep; 54(3):240-5. PubMed ID: 19661812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of celastrol on myocardial ischemia-reperfusion injury.
    Li X; Wu N; Zou L; Jia D
    Anatol J Cardiol; 2017 Dec; 18(6):384-390. PubMed ID: 29256892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A.
    Guo J; Shirozu K; Akahoshi T; Mizuta Y; Murata M; Yamaura K
    Int Immunopharmacol; 2020 Jun; 83():106462. PubMed ID: 32251961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.